| Users, % | Non-users, % | Crude RRa | Adjusted RRa,b |
---|---|---|---|---|
30-day mortality | Â | Â | Â | Â |
Statins | Â | Â | Â | Â |
  No AF | 15.8 (15.1–16.5) | 16.1 (15.8–16.5) | 0.98 (0.93–1.03) | 0.83 (0.79–0.88) |
  AF | 23.6 (21.7–25.7) | 28.4 (26.9–30.0) | 0.83 (0.75–0.92) | 0.93 (0.84–1.04) |
Aspirin | Â | Â | Â | Â |
  No AF | 20.1 (19.3–20.8) | 15.0 (14.7–15.4) | 1.34 (1.28–1.40) | 0.93 (0.88–0.97) |
  AF | 28.2 (26.3–30.3) | 25.9 (24.4–27.5) | 1.09 (0.99–1.20) | 0.99 (0.91–1.09) |
Vitamin K antagonists | Â | Â | Â | Â |
  No AF | 23.3 (21.1–25.7) | 15.9 (15.5–1.62) | 1.47 (1.33–1.62) | 1.07 (0.97–1.19) |
  AF | 22.9 (21.3–24.6) | 30.6 (28.9–32.4) | 0.75 (0.68–0.82) | 0.91 (0.82–1.00) |
Beta-blockers | Â | Â | Â | Â |
  No AF | 17.2 (16.4–17.9) | 15.8 (15.4–16.1) | 1.09 (1.02–1.12) | 0.91 (0.86–0.95) |
  AF | 26.4 (24.8–28.1) | 27.3 (25.5–29.2) | 0.97 (0.88–1.06) | 1.07 (0.98–1.18) |
Non-dihydropyridine CCBs | Â | Â | Â | Â |
  No AF | 21.4 (18.9–24.3) | 16.0 (15.6–16.3) | 1.34 (1.18–1.52) | 1.04 (0.92–1.17) |
  AF | 24.2 (20.1–28.9) | 27.0 (25.8–28.3) | 0.90 (0.74–1.08) | 0.86 (0.71–1.03) |
Digoxin | Â | Â | Â | Â |
  No AF | 32.7 (29.6–36.2) | 15.8 (15.5–16.1) | 2.07 (1.87–2.30) | 1.15 (1.03–1.28) |
  AF | 29.5 (27.4–31.8) | 25.5 (24.0–27.0) | 1.16 (1.05–1.27) | 0.97 (0.88–1.07) |
Amiodarone | Â | Â | Â | Â |
  No AF | 25.2 (18.3–34.2) | 16.0 (15.7–16.3) | 1.58 (1.15–2.16) | 1.08 (0.83–1.42) |
  AF | 27.3 (23.0–32.2) | 26.8 (25.5 -28.0) | 1.02 (0.86–1.21) | 1.15 (0.98 -1.34) |
365-day mortality | Â | Â | Â | Â |
Statins | Â | Â | Â | Â |
  No AF | 24.8 (24.0–25.6) | 25.6 (25.1–26.0) | 0.97 (0.94–1.01) | 0.82 (0.79–0.86) |
  AF | 36.7 (34.5–39.1) | 43.1 (41.4–44.8) | 0.85 (0.79–0.92) | 0.95 (0.88–1.02) |
Aspirin | Â | Â | Â | Â |
  No AF | 31.0 (30.2–31.9) | 23.9 (23.5–24.4) | 1.30 (1.25–1.34) | 0.93 (0.90–0.96) |
  AF | 42.7 (40.6–44.9) | 39.8 (38.1–41.5) | 1.07 (1.00–1.15) | 1.00 (0.94–1.06) |
Vitamin K antagonists | Â | Â | Â | Â |
  No AF | 37.8 (35.3–40.5) | 25.1 (24.7–25.5) | 1.51 (1.41–1.62) | 1.11 (1.03–1.19) |
  AF | 35.4 (33.5–37.3) | 46.3 (44.4–48.3) | 0.76 (0.71–0.82) | 0.91 (0.85–0.97) |
Beta-blockers | Â | Â | Â | Â |
  No AF | 26.9 (26.0–27.7) | 25.1 (24.6–25.5) | 1.07 (1.03–1.11) | 0.89 (0.86–0.93) |
  AF | 39.4 (37.6–41.3) | 42.7 (40.7–44.8) | 0.92 (0.86–0.99) | 1.00 (0.95–1.07) |
Non-dihydropyridine CCBs | Â | Â | Â | Â |
  No AF | 33.3 (30.3–36.5) | 25.3 (24.8–25.6) | 1.32 (1.20–1.45) | 1.02 (0.94–1.11) |
  AF | 39.4 (34.6–44.7) | 41.0 (39.6–42.4) | 0.96 (0.84–1.10) | 0.93 (0.82–1.05) |
Digoxin | Â | Â | Â | Â |
  No AF | 50.1 (46.6–53.6) | 25.0 (24.7–25.4) | 2.00 (1.86–2.15) | 1.16 (1.08–1.24) |
  AF | 45.0 (42.6 -47.4) | 38.9 (37.3–40.6) | 1.15 (1.08–1.24) | 1.01 (0.95–1.08) |
Amiodarone | Â | Â | Â | Â |
  No AF | 44.4 (35.8–53.9) | 25.4 (25.0–25.7) | 1.75 (1.42–2.15) | 1.18 (0.99–1.41) |
  AF | 42.2 (37.3–47.4) | 40.8 (39.4–42.2) | 1.03 (0.91–1.17) | 1.12 (1.01–1.25) |